文献速递肝病

长期奥贝胆酸治疗改善原发性胆汁性胆管炎患者组织学终点

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-10-10

POISE试验肝脏活检亚组研究纳入17例对熊去氧胆酸不耐受或应答不佳的原发性胆汁性胆管炎患者,双盲阶段入组时及OCA治疗3年后行肝活检。3年OCA治疗使多数患者纤维化、胆管损伤等组织学特征改善或稳定,胶原形态计量学指标显著下降。

要点

  • 长期OCA治疗可改善或稳定PBC患者胆管损伤及纤维化等组织学特征
  • OCA治疗3年后胶原面积比、纤维密度等定量纤维化指标显著降低
  • 该亚组分析样本量小,组织学获益需更大样本验证

核心结论

  • POISE研究亚组分析显示,PBC患者长期OCA治疗与疾病特征(包括胆管损伤、纤维化及胶原形态计量学特征)的改善或稳定相关。

研究设计与样本

  • POISE为3期双盲、安慰剂对照、随机试验,含5年开放标签扩展期,评估每日5至10 mg OCA用于对熊去氧胆酸不耐受或应答不佳的患者。
  • 肝脏活检亚组从17例患者在双盲阶段入组时及OCA治疗3年后收集肝活检标本。
  • 组织学评估由2名病理学家以盲法、随机方式进行;胶原形态计量学采用自动二次谐波发生和双光子激发显微镜评估。

主要发现

  • 从入组至治疗3年,多数患者纤维化(71%)、胆管丢失(76%)、小胆管减少(82%)、胆管反应(82%)、界面性肝炎(100%)和小叶性肝炎(94%)改善或稳定。

临床怎么用

  • 对于对熊去氧胆酸不耐受或应答不佳的PBC患者,长期OCA治疗可能带来组织学层面的纤维化及胆管损伤改善或稳定。

局限性

  • 肝脏活检亚组仅纳入17例患者,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary biliary cholangitis (PBC) is an autoimmune disease characterized by bile duct destruction that can progress to cirrhosis. A liver biopsy substudy was conducted in the PBC obeticholic acid (OCA) International Study of Efficacy (POISE) to determine the long-term effects of OCA on liver damage and fibrosis in patients with PBC. POISE is a phase 3, double-blind, placebo-controlled, randomized trial with a 5-year open-label extension that evaluated 5 to 10 mg OCA daily in patients who were intolerant or unresponsive to ursodeoxycholic acid. METHODS: Liver biopsy specimens were collected from 17 patients at time of enrollment in the double-blind phase and after 3 years of OCA treatment. Histologic evaluations were performed by 2 pathologists in a blinded, randomized fashion to determine the effects of OCA on fibrosis and other histologic parameters. Collagen morphometry assessments were performed by automated second harmonic generation and 2-photon excitation microscopy to observe quantitative measures of fibrosis. RESULTS: From the time of enrollment until 3 years of treatment, most patients had improvements or stabilization in fibrosis (71%), bile duct loss (76%), ductopenia (82%), ductular reaction (82%), interface hepatitis (100%), and lobular hepatitis (94%). Over the 3-year period, we found significant reductions in collagen area ratio (median, -2.1; first quartile, -4.6, third quartile, -0.3; P = .013), collagen fiber density (median, -0.8; first quartile, -2.5; third quartile, 0; P = .021), collagen reticulation index (median, -0.1; first quartile, -0.3; third quartile, 0; P = .008), and fibrosis composite score (median, -1.0; first quartile, -2.5; third quartile, -0.5; P = .002). CONCLUSIONS: A subanalysis of data from the POISE study showed that long-term OCA treatment in patients with PBC is associated with improvements or stabilization of disease features, including ductular injury, fibrosis, and collagen morphometry features (ClinicalTrials.gov no: NCT01473524 and EudraCT no: 2011-004728-36).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bowlus CL, Pockros PJ, Kremer AE, et al. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2019. PMID: 31606455. doi:10.1016/j.cgh.2019.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。